Why European and United States drug regulators are not speaking with one voice on anti-influenza drugs: regulatory review methodologies and the importance of ‘deep’ product reviews

Why European and United States drug regulators are not speaking with one voice on anti-influenza drugs: regulatory review methodologies and the importance of ‘deep’ product reviews

Abstract Background Relenza represents the first neuraminidase inhibitor (NI), a class of drugs that also includes the drug Tamiflu. Although heralded as breakthrough treatments in influenza, NI efficacy has remained highly controversial. A key unsettled question is why the United States Food and Dr...

Full description

Bibliographic Details
Main Authors: Shai Mulinari, Courtney Davis
Format: Article
Language:English
Published: BMC 2017-11-01
Series:Health Research Policy and Systems
Subjects:
Neuraminidase inhibitor
Influenza
Meta-analysis
United States Food and Drug Administration
European Medicines Agency
Online Access:http://link.springer.com/article/10.1186/s12961-017-0259-8

Internet

http://link.springer.com/article/10.1186/s12961-017-0259-8

Similar Items